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Regarding “Endovascular versus surgical treatment
for thrombosed hemodialysis: a prospective,
randomized study”
To the Editors:
The recent article by Dougherty et al (J Vasc Surg
1999;30:1016-23) revisits several issues regarding throm-
bosed hemodialysis grafts. A flawed study design, insuffi-
cient information on the endovascular techniques used,
and an incomplete cost analysis limit the applicability of
the conclusions.
The study design lacks blinding. Despite randomiza-
tion of the patients, there is potential for outcome bias
when the same investigator performs both procedures.
Deliverers of the therapies that are being directly com-
pared for efficacy need to be blinded to the ongoing
results of the study to ensure scientific integrity and pre-
vent outcome bias.
The current endovascular technique for treatment of
thrombosed hemodialysis grafts is mechanical catheter
therapy. Urokinase is no longer commercially available
because the Food and Drug Administration detected a
number of problems regarding the processing and manu-
facturing of this drug.1 Mechanical catheter therapy has
been validated against both thrombolytic therapy and sur-
gical therapy. In comparison with thrombolytic therapy,
mechanical thrombectomy required less procedure time
(75 minutes vs 89 minutes, P < .04) with equivalent 3-
month patency as reported by Trerotola et al in 1998.2
According to Uflacker et al in 1996,3 mechanical therapy
was similar in initial technical success, primary patency,
and secondary patency to surgical thrombectomy.
Another point is the question of central venous steno-
sis as a cause for graft failure. Marston et al4 recently
reported central venous stenosis as a cause of graft failure
in 15% of patients. In the interventional radiology suite,
the central veins are routinely studied, and undergo fistu-
lography. In this paper there is no mention of central
venous evaluation. The cause of graft failure was not iden-
tified in seven (9%) of 80 patients. It is possible that cen-
tral venous stenosis was missed causing graft rethrombo-
sis. The information gathered by central venography is
also useful in planning further graft placement.4
The authors fail to report the type of endovascular
equipment used. How often was a second balloon needed?
Furthermore, the average amount of urokinase used per
patient is not reported. Urokinase is supplied in vials con-
taining 250,000 units. How often was a second vial need-
ed? Only rarely is more than one vial needed.
The cost analysis in this study as justification for use of
surgical thrombectomy over endovascular therapy is prob-
lematic. Dougherty et al report longer procedure times and
increased cost for endovascular therapy. However, Marston
et al4 reported equivalent costs between pulse-spray throm-
bolysis and surgical thrombectomy. Total procedure time is
variable and dependent on the expertise of the physician,
the complexity of the hemodialysis graft, and the venous
lesion to be treated. Most endovascular therapy is per-
formed in the radiology department, and therefore, a valid
cost comparison compels the investigators to use radiology
costs versus operating room costs. We speculate that the
reported increased cost and time of the endovascular proce-
dures may be operator dependent, institutional dependent,
and device dependent. Furthermore, the large number of
patients crossed over into the surgical thrombectomy arm
from the endovascular arm may represent the technical bias
of the investigators when faced with a complicated lesion.
The real issue is the optimization of patient care. This
is best achieved with a complementary approach between
the two therapies, each of which has its strengths and
weaknesses. A combined multimodality approach is need-
ed with refined algorithms to select the patients with the
appropriate indications who will most benefit from the
chosen therapy. Thus, multispecialty coordination among
nephrologists, vascular surgeons, and interventional radi-
ologists is needed to enhance patient care.5
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Reply
Drs Farner and Sehgal raise several criticisms of our
study. With regard to “blinding,” this generally refers to
the evaluator of outcome being blinded to the treatment
group of a patient, which is impracticable (surgical
patients obviously have incisions) and unnecessary (the
primary end point of graft thrombosis is an objective
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